The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 13 rounds in the feed, most often at Series A and in Biotech.
Venture capitalforbion.comRounds from 2023-06-06 to 2026-09-16
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Sling Therapeutics A biopharmaceutical company advancing oral linsitinib for thyroid eye disease | Series C Verified against 1 of 20 sources | $123M | 2026-09-16 | [ LEAD ] |
Solstice Oncology Solstice Oncology develops immuno-oncology therapies aimed at treating early-stage cancers, specifically targeting colon cancer. | Series A |
| $225M |
| 2026-09-09 |
| [ PART ] |
RQ Bio Series A | Series A Verified against 1 of 6 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $115M | 2026-06-24 | [ PART ] |
CellCentric A drug-discovery platform | Series D Verified against 4 of 7 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $220M | 2026-05-06 | [ PART ] |
Coultreon Biopharma Develop autoimmune disease treatments | Series A Verified against 1 of 5 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $125M | 2026-04-28 | [ LEAD ] |
Slate Medicines Next-generation therapeutics for migraine and headache disorders targeting pathways involved in migraine pathophysiology. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $130M | 2026-02-24 | [ LEAD ] |
AAVantgarde AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet need | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $141M | 2025-11-03 | [ PART ] |
Expedition Therapeutics Expedition Therapeutics develops novel treatments for inflammatory and respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD). | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2025-10-09 | [ PART ] |
CellCentric A drug-discovery platform | Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-05-19 | [ LEAD ] |
Granite Bio Granitebio is a biotechnology company developing innovative therapies focusing on inflammatory, autoimmune, and fibrotic diseases with first-in-class antibodies. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $70M | 2025-04-24 | [ LEAD ] |
Verdiva Bio Verdiva Bio develops next-generation medicines aimed at treating obesity and cardiometabolic diseases. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $411M | 2025-01-09 | [ LEAD ] |
Airna AIRNA develops RNA editing therapeutics aimed at delivering functional cures for patients with rare diseases and common conditions. | Series A Verified against 1 of 6 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60M | 2024-07-31 | [ LEAD ] |
AAVantgarde AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet need | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $65.2M | 2023-06-06 | [ LEAD ] |